Chest
-
AsthmaSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: The progression and development of asthma across the menopausal transition has not been thoroughly addressed, or clearly separated from the effects of age. The present study evaluates the effects of menopause on asthma severity, quality of life and healthcare utilization using a propensity score model. ⋯ Suzy Comhair: Grant monies (from sources other than industry): NIH (HL69170) The following authors have nothing to disclose: Joe Zein, Eugene Bleecker, William Busse, William Calhoun, Mario Castro, K. Fan Chung, Raed Dweik, Anne Fitzpatrick, Benjamin Gaston, Elliot Israel, Nizar Jarjour, Wendy Moore, Gerald Teague, Sally Wenzel, Serpil ErzurumNo Product/Research Disclosure Information.
-
Surgery CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Thymoma show a variable and unpredictable evolution, ranging from an indolent non-invasive attitude to a highly infiltrative and metastasising one. For invasive thymoma, the optimal treatment method remains controversial. We present the case of a woman with a thymoma with pleural and pericardial dissemination who received multimodality therapy. ⋯ The following authors have nothing to disclose: Rocio Carrera-Ceron, Juan Jacinto-Tinajero, Luis Marcelo Argote Greene, Patricio Santillán DohertyNo Product/Research Disclosure Information.
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To evaluate the general and clinical characteristics of patients with and without coexistent pneumonia during admission for AECOPD. ⋯ The following authors have nothing to disclose: Sana' AL Aqqad, Irfhan Ali Hyder Ali, Balamurugan TangiisuranNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: With the burden of COPD increasing, new treatment strategies to optimize pharmacotherapy include combination therapies with complementary modes of action. This phase 3 trial evaluated efficacy and safety of fixed-dose combinations of aclidinium, a long-acting anticholinergic indicated for maintenance treatment of COPD-associated bronchospasm, and formoterol, a long-acting β2-agonist, in moderate to severe COPD patients. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Dr. D'Urzo has received research, consulting and lecturing fees from GlaxoSmithKline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Stephen Rennard: Consultant fee, speaker bureau, advisory committee, etc.: Stephen Rennard has received honoraria for lectures from AARC, Almirall, Am Col Osteopathic Physicians, Asan Medical Center, American Thoracic Society, California Society of Allergy, CME Incite, COPD Foundation, Creative Educational Concepts, Dey, Duke University, Forest, France Foundation, HSC Medical Education, Information TV, Lung Association, Novartis (Horsham, Nycomed, Otsuka, PeerVoice, Pfizer, Shaw Science, University of Washington, University of Alabama Birmingham, VA Sioux Falls., Consultant fee, speaker bureau, advisory committee, etc.: Stephen Rennard has also received honorarium for consulting with the following: ABIM, Able Associates, Adelphi Research, Align2Acton, Almirall/Prescott, APT Pharma/Britnall, Astra-Zeneca, American Thoracic Society Beilenson, Boehringer Ingelheim, Boehringer Ingelheim (ACCP), BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clarus Acuity, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Dunn Group, Easton Associates, Equinox, and Forest., Consultant fee, speaker bureau, advisory committee, etc.: (continued) Frankel Group, Fulcrum, Gerson Lehman, Globe Life Sciences, Guidepoint, Health Advanced, Hoffman LaRoche, Informed, Insyght, KOL Connection, Leerink Swan, M. Pankove, McKinsey, MDRxFinancial, Medimmune, Merck, Novartis, Nycomed, Oriel, Osterman, Peal, Penn Technology, Pennside, Pfizer, PharmaVentures, Pharmaxis, Prescott, Price Waterhouse, Propagate, Pulmonary Reviews, Pulmatrix, Reckner Associates, Recruiting Resource, Roche, Sankyo, Schering, and Schlesinger., Consultant fee, speaker bureau, advisory committee, etc.: (continued) Scimed, Smith Research, Sudler and Hennessey, Summer Street Research, Talecris, Think Equity, UBC, Uptake Medical, Vantage Point Management. Victor Mergel: Employee: Victor Mergel is an employee of Forest Research Institute, Inc. Esther Garcia Gil: Employee: Esther Garcia Gil is an employee of Almirall S.A. Anne Leselbaum: Employee: Anne Leselbaum is an employee of Almirall S.A. Cynthia Caracta: Employee: C. Caracta is an employee of Forest Research Institute, Inc. , Shareholder: C. Caracta is a stockowner and has received stock options from Forest Laboratories, Inc.Aclidinium bromide (Tudorzo/Pressair, Eklira/Genuair, Breo/Ellipta) is approved for the maintenance treatment of COPD-associated bronchspasm. The fixed-dose combination of aclidinium bromide/formoterol fumarate is being developed, but not yet approved, for its commercial use for the treatment of COPD.
-
Thoracic SurgerySESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Surgical treatment for colorectal cancer (CRC) lung metastases requires resection of all malignant lesions. Computed Tomography (CT) findings may not agree with pathological ones. This lack of agreement can result in incomplete resection. The aim of this study was to estimate the determinants of disagreement between findings provided by CT and surgical pathology in patients undergoing removal of CRC lung lesions. ⋯ The following authors have nothing to disclose: Carmen Marron Fernandez, Javier de la Cruz, David Lora, Pablo Gamez, Juan Jose Rivas, Raul Embun, Laureano MolinsNo Product/Research Disclosure Information.